Copyright Reports & Markets. All rights reserved.

Global Human Coagulation Factor VIII Market Insights, Forecast to 2025

Request for Sample of this report
Buy now

Table of Contents

    1 Study Coverage

    • 1.1 Human Coagulation Factor VIII Product
    • 1.2 Market Segments
    • 1.3 Key Manufacturers Covered
    • 1.4 Market by Type
      • 1.4.1 Global Human Coagulation Factor VIII Market Size Growth Rate by Product
      • 1.4.2 Recombinant Factor VIII
      • 1.4.3 Plasma-derived Factor VIII
    • 1.5 Market by End User
      • 1.5.1 Global Human Coagulation Factor VIII Market Size Growth Rate by End User
      • 1.5.2 Hemophilia A
      • 1.5.3 Spontanous / Trauma
      • 1.5.4 Surgical
      • 1.5.5 Other
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Executive Summary

    • 2.1 Global Human Coagulation Factor VIII Market Size
      • 2.1.1 Global Human Coagulation Factor VIII Revenue 2014-2025
      • 2.1.2 Global Human Coagulation Factor VIII Sales 2014-2025
    • 2.2 Human Coagulation Factor VIII Growth Rate by Regions
      • 2.2.1 Global Human Coagulation Factor VIII Sales by Regions
      • 2.2.2 Global Human Coagulation Factor VIII Revenue by Regions

    3 Breakdown Data by Manufacturers

    • 3.1 Human Coagulation Factor VIII Sales by Manufacturers
      • 3.1.1 Human Coagulation Factor VIII Sales by Manufacturers
      • 3.1.2 Human Coagulation Factor VIII Sales Market Share by Manufacturers
      • 3.1.3 Global Human Coagulation Factor VIII Market Concentration Ratio (CR5 and HHI)
    • 3.2 Human Coagulation Factor VIII Revenue by Manufacturers
      • 3.2.1 Human Coagulation Factor VIII Revenue by Manufacturers (2014-2019)
      • 3.2.2 Human Coagulation Factor VIII Revenue Share by Manufacturers (2014-2019)
    • 3.3 Human Coagulation Factor VIII Price by Manufacturers
    • 3.4 Human Coagulation Factor VIII Manufacturing Base Distribution, Product Types
      • 3.4.1 Human Coagulation Factor VIII Manufacturers Manufacturing Base Distribution, Headquarters
      • 3.4.2 Manufacturers Human Coagulation Factor VIII Product Type
      • 3.4.3 Date of International Manufacturers Enter into Human Coagulation Factor VIII Market
    • 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Product

    • 4.1 Global Human Coagulation Factor VIII Sales by Product
    • 4.2 Global Human Coagulation Factor VIII Revenue by Product
    • 4.3 Human Coagulation Factor VIII Price by Product

    5 Breakdown Data by End User

    • 5.1 Overview
    • 5.2 Global Human Coagulation Factor VIII Breakdown Data by End User

    6 North America

    • 6.1 North America Human Coagulation Factor VIII by Countries
      • 6.1.1 North America Human Coagulation Factor VIII Sales by Countries
      • 6.1.2 North America Human Coagulation Factor VIII Revenue by Countries
      • 6.1.3 United States
      • 6.1.4 Canada
      • 6.1.5 Mexico
    • 6.2 North America Human Coagulation Factor VIII by Product
    • 6.3 North America Human Coagulation Factor VIII by End User

    7 Europe

    • 7.1 Europe Human Coagulation Factor VIII by Countries
      • 7.1.1 Europe Human Coagulation Factor VIII Sales by Countries
      • 7.1.2 Europe Human Coagulation Factor VIII Revenue by Countries
      • 7.1.3 Germany
      • 7.1.4 France
      • 7.1.5 UK
      • 7.1.6 Italy
      • 7.1.7 Russia
    • 7.2 Europe Human Coagulation Factor VIII by Product
    • 7.3 Europe Human Coagulation Factor VIII by End User

    8 Asia Pacific

    • 8.1 Asia Pacific Human Coagulation Factor VIII by Countries
      • 8.1.1 Asia Pacific Human Coagulation Factor VIII Sales by Countries
      • 8.1.2 Asia Pacific Human Coagulation Factor VIII Revenue by Countries
      • 8.1.3 China
      • 8.1.4 Japan
      • 8.1.5 Korea
      • 8.1.6 India
      • 8.1.7 Australia
      • 8.1.8 Indonesia
      • 8.1.9 Malaysia
      • 8.1.10 Philippines
      • 8.1.11 Thailand
      • 8.1.12 Vietnam
      • 8.1.13 Singapore
    • 8.2 Asia Pacific Human Coagulation Factor VIII by Product
    • 8.3 Asia Pacific Human Coagulation Factor VIII by End User

    9 Central & South America

    • 9.1 Central & South America Human Coagulation Factor VIII by Countries
      • 9.1.1 Central & South America Human Coagulation Factor VIII Sales by Countries
      • 9.1.2 Central & South America Human Coagulation Factor VIII Revenue by Countries
      • 9.1.3 Brazil
    • 9.2 Central & South America Human Coagulation Factor VIII by Product
    • 9.3 Central & South America Human Coagulation Factor VIII by End User

    10 Middle East and Africa

    • 10.1 Middle East and Africa Human Coagulation Factor VIII by Countries
      • 10.1.1 Middle East and Africa Human Coagulation Factor VIII Sales by Countries
      • 10.1.2 Middle East and Africa Human Coagulation Factor VIII Revenue by Countries
      • 10.1.3 GCC Countries
      • 10.1.4 Turkey
      • 10.1.5 Egypt
      • 10.1.6 South Africa
    • 10.2 Middle East and Africa Human Coagulation Factor VIII by Product
    • 10.3 Middle East and Africa Human Coagulation Factor VIII by End User

    11 Company Profiles

    • 11.1 Shire (Baxter)
      • 11.1.1 Shire (Baxter) Company Details
      • 11.1.2 Company Business Overview
      • 11.1.3 Shire (Baxter) Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2014-2019)
      • 11.1.4 Shire (Baxter) Human Coagulation Factor VIII Products Offered
      • 11.1.5 Shire (Baxter) Recent Development
    • 11.2 Bayer
      • 11.2.1 Bayer Company Details
      • 11.2.2 Company Business Overview
      • 11.2.3 Bayer Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2014-2019)
      • 11.2.4 Bayer Human Coagulation Factor VIII Products Offered
      • 11.2.5 Bayer Recent Development
    • 11.3 CSL
      • 11.3.1 CSL Company Details
      • 11.3.2 Company Business Overview
      • 11.3.3 CSL Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2014-2019)
      • 11.3.4 CSL Human Coagulation Factor VIII Products Offered
      • 11.3.5 CSL Recent Development
    • 11.4 Pfizer
      • 11.4.1 Pfizer Company Details
      • 11.4.2 Company Business Overview
      • 11.4.3 Pfizer Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2014-2019)
      • 11.4.4 Pfizer Human Coagulation Factor VIII Products Offered
      • 11.4.5 Pfizer Recent Development
    • 11.5 Grifols
      • 11.5.1 Grifols Company Details
      • 11.5.2 Company Business Overview
      • 11.5.3 Grifols Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2014-2019)
      • 11.5.4 Grifols Human Coagulation Factor VIII Products Offered
      • 11.5.5 Grifols Recent Development
    • 11.6 Biogen
      • 11.6.1 Biogen Company Details
      • 11.6.2 Company Business Overview
      • 11.6.3 Biogen Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2014-2019)
      • 11.6.4 Biogen Human Coagulation Factor VIII Products Offered
      • 11.6.5 Biogen Recent Development
    • 11.7 Octapharma
      • 11.7.1 Octapharma Company Details
      • 11.7.2 Company Business Overview
      • 11.7.3 Octapharma Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2014-2019)
      • 11.7.4 Octapharma Human Coagulation Factor VIII Products Offered
      • 11.7.5 Octapharma Recent Development
    • 11.8 NovoNordisk
      • 11.8.1 NovoNordisk Company Details
      • 11.8.2 Company Business Overview
      • 11.8.3 NovoNordisk Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2014-2019)
      • 11.8.4 NovoNordisk Human Coagulation Factor VIII Products Offered
      • 11.8.5 NovoNordisk Recent Development
    • 11.9 Greencross
      • 11.9.1 Greencross Company Details
      • 11.9.2 Company Business Overview
      • 11.9.3 Greencross Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2014-2019)
      • 11.9.4 Greencross Human Coagulation Factor VIII Products Offered
      • 11.9.5 Greencross Recent Development
    • 11.10 Kedrion
      • 11.10.1 Kedrion Company Details
      • 11.10.2 Company Business Overview
      • 11.10.3 Kedrion Human Coagulation Factor VIII Sales, Revenue and Gross Margin (2014-2019)
      • 11.10.4 Kedrion Human Coagulation Factor VIII Products Offered
      • 11.10.5 Kedrion Recent Development
    • 11.11 BPL
    • 11.12 Hualan Bio
    • 11.13 RAAS

    12 Future Forecast

    • 12.1 Human Coagulation Factor VIII Market Forecast by Regions
      • 12.1.1 Global Human Coagulation Factor VIII Sales Forecast by Regions 2019-2025
      • 12.1.2 Global Human Coagulation Factor VIII Revenue Forecast by Regions 2019-2025
    • 12.2 Human Coagulation Factor VIII Market Forecast by Product
      • 12.2.1 Global Human Coagulation Factor VIII Sales Forecast by Product 2019-2025
      • 12.2.2 Global Human Coagulation Factor VIII Revenue Forecast by Product 2019-2025
    • 12.3 Human Coagulation Factor VIII Market Forecast by End User
    • 12.4 North America Human Coagulation Factor VIII Forecast
    • 12.5 Europe Human Coagulation Factor VIII Forecast
    • 12.6 Asia Pacific Human Coagulation Factor VIII Forecast
    • 12.7 Central & South America Human Coagulation Factor VIII Forecast
    • 12.8 Middle East and Africa Human Coagulation Factor VIII Forecast

    13 Market Opportunities, Challenges, Risks and Influences Factors Analysis

    • 13.1 Market Opportunities and Drivers
    • 13.2 Market Challenges
    • 13.3 Market Risks/Restraints
    • 13.4 Macroscopic Indicators

    14 Value Chain and Sales Channels Analysis

    • 14.1 Value Chain Analysis
    • 14.2 Human Coagulation Factor VIII Customers
    • 14.3 Sales Channels Analysis
      • 14.3.1 Sales Channels
      • 14.3.2 Distributors

    15 Research Findings and Conclusion

      16 Appendix

      • 16.1 Research Methodology
        • 16.1.1 Methodology/Research Approach
        • 16.1.2 Data Source
      • 16.2 Author Details

      Human Coagulation Factor VIII is an essential blood-clotting protein, also known as anti-hemophilic factor (AHF). In humans, factor VIII is encoded by the F8 gene, defects in this gene results in hemophilia A.
      North America is the largest consumption market of Human Coagulation Factor VIII, with sales market share nearly 46%. And the production market share of Human Coagulation Factor VIII is 58%. The manufacturers of Human Coagulation Factor VIII in North America have big and medium scale.

      The second place is Europe, following North America with the sales market share of 36% and the production market share over 28%. Many European players have plants in USA due to rich plasma source. So there are a large number of Human Coagulation Factor VIIIs for import from other regions.

      Asia is another important market of Human Coagulation Factor VIII, enjoying 10% production market share and 11% sales market share. Especially in China, the sales and price of Factor VIII are controlled by country, and the price in China is different from other regions.

      Main players are from USA and Europe, like Baxter, Bayer, and they have many plants in other regions. China also can supply Human Coagulation Factor VIII, but the products are mainly consumed in China.

      Market competition is intense. Baxter, Bayer, CSL, Pfizer, Grifols, etc. are the leaders of the industry, and hold key technologies, with high-end customers, have been formed in the monopoly position in the industry. However, with further expanding market, there will be more manufactures in the future.

      The global Human Coagulation Factor VIII market is valued at 7440 million US$ in 2018 and will reach 9420 million US$ by the end of 2025, growing at a CAGR of 3.0% during 2019-2025. The objectives of this study are to define, segment, and project the size of the Human Coagulation Factor VIII market based on company, product type, end user and key regions.

      This report studies the global market size of Human Coagulation Factor VIII in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Human Coagulation Factor VIII in these regions.
      This research report categorizes the global Human Coagulation Factor VIII market by top players/brands, region, type and end user. This report also studies the global Human Coagulation Factor VIII market status, competition landscape, market share, growth rate, future trends, market drivers, opportunities and challenges, sales channels and distributors.

      The following manufacturers are covered in this report, with sales, revenue, market share for each company:
      Shire (Baxter)
      Bayer
      CSL
      Pfizer
      Grifols
      Biogen
      Octapharma
      NovoNordisk
      Greencross
      Kedrion
      BPL
      Hualan Bio
      RAAS

      Market size by Product
      Recombinant Factor VIII
      Plasma-derived Factor VIII
      Market size by End User
      Hemophilia A
      Spontanous / Trauma
      Surgical
      Other

      Market size by Region
      North America
      United States
      Canada
      Mexico
      Asia-Pacific
      China
      India
      Japan
      South Korea
      Australia
      Indonesia
      Singapore
      Malaysia
      Philippines
      Thailand
      Vietnam
      Europe
      Germany
      France
      UK
      Italy
      Spain
      Russia
      Central & South America
      Brazil
      Rest of Central & South America
      Middle East & Africa
      GCC Countries
      Turkey
      Egypt
      South Africa

      The study objectives of this report are:
      To study and analyze the global Human Coagulation Factor VIII market size (value & volume) by company, key regions, products and end user, breakdown data from 2014 to 2018, and forecast to 2025.
      To understand the structure of Human Coagulation Factor VIII market by identifying its various subsegments.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      Focuses on the key global Human Coagulation Factor VIII companies, to define, describe and analyze the sales volume, value, market share, market competition landscape and recent development.
      To project the value and sales volume of Human Coagulation Factor VIII submarkets, with respect to key regions.
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

      In this study, the years considered to estimate the market size of Human Coagulation Factor VIII are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      This report includes the estimation of market size for value (million US$) and volume (K Units). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Human Coagulation Factor VIII market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now